The intention and objective of this study is to primarily understand the safety and tolerability profile of AXA1125 and AXA1957 when administered to subjects with NAFLD. The study would also add to the body of knowledge regarding the role(s) of amino acids in hepatic physiology.
|Principal Investigator||Rashmee Patil, MD|
|Sponsor||Axcella Health Inc.|
|Type of Trial||Interventional|